Pharmaceutical Companies Ramp Up M&A Activities to Enrich Pipelines and Boost Financial Performance

　　【Pharmaceutical Network Industry Dynamics】In recent times, there have been frequent acquisition activities by pharmaceutical companies both in and outside of China. Within China, on the evening of March 18th, Aladdin, a manufacturer of scientific research reagents, announced its intention to acquire 51% of Shanghai YuanYe Biotechnology Co., Ltd. for 1.81 billion yuan. Following the completion of the acquisition, YuanYe Biotechnology will become a controlling subsidiary within Aladdin's consolidated financial statements.
 

According to the disclosure, YuanYe Biology mainly engages in the research and development, production, and sales of scientific reagents, including biochemical reagents,Reference Standard, small molecule inhibitors, liquid reagents and other related products have obvious advantages. Its performance is outstanding, achieving a revenue of 105 million yuan in 2023, with a net profit of 36.8213 million yuan. In January 2024, the revenue was 10.3679 million yuan, with a net profit of 3.9244 million yuan.
 

In recent years, Aladdin has faced significant pressure on its operating performance. In 2023, Aladdin achieved revenue of 403 million yuan, a slight increase of 6.60% year-on-year, while the net profit attributable to shareholders was 83.2819 million yuan, a year-on-year decrease of 9.80%.
 

In this regard, the industry expects that Aladdin's acquisition of Yuan Ye Bio may play a role in "polishing" performance. Based on the financial data from 2023, it is estimated that after the merger of Aladdin and Yuan Ye Bio, revenue and profit levels will increase by 25.93% and 44.21%, respectively.
 

Aladdin stated that through this acquisition, the company can enrich its biochemical reagent product line, fill the gap in this aspect, and form a good synergy with Yuan Ye Bio.
 

Apart from Aladdin, on March 1, Heze Saituo Biological Technology Co.,Ltd. announced that the company plans to acquire 60% of YinGu Pharmaceutical Co., Ltd., which owns independent intellectual property rights for Class 1 innovative drugs, for a cash payment of 458 million yuan. This move aims to further improve the company's industrial chain layout and help achieve industrial upgrading.
 

Guiyang Xintian Pharmaceutical Co., Ltd. recently announced that the company is planning to issue shares to some shareholders of Shanghai Hui Lun Pharmaceutical Co., Ltd., a small molecule chemical pharmaceutical enterprise, to acquire their equity in Hui Lun Pharmaceutical. After the completion of this transaction, Hui Lun Pharmaceutical will become a wholly-owned subsidiary of the company. Regarding this transaction, Guiyang Xintian Pharmaceutical stated that, upon completion, the listed company will further enrich its product pipeline in specialized fields. At the same time, Guiyang Xintian Pharmaceutical will integrate the market promotion resources of both parties, deeply integrate in disease areas such as gynecology and andrology, improve the marketing efficiency of drugs used within the same department, enrich doctors' choices, and simultaneously expand the layout and sales coverage of OTC, e-commerce, and other sales channels for coordinated development.
 

China Resources Double-Crane announced in late February that the company plans to acquire 100% of China Resources Zizhu held by Beijing Pharmaceutical Group Co., Ltd. for approximately 31.15 billion yuan. China Resources Double-Crane stated that this transaction is an important step in the integration of the chemical pharmaceuticals sector of China Resources Group. By injecting high-quality assets into China Resources Double-Crane, it will further promote strategic restructuring and professional integration, thereby enhancing the quality of the listed company. This transaction will help the company further amplify its competitive advantages and improve future performance, bringing considerable investment returns. At the same time, it will also further enrich the company’s product line in specialized fields.
 

Overseas, on March 14, AstraZeneca announced that it had signed an agreement to acquire Amolyt Pharma, a company that develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Regarding this acquisition, AstraZeneca stated that it would strengthen AstraZeneca's late-stage rare disease pipeline, Alexion, and expand its bone metabolism franchise.
 

The industry believes that currently, the pharmaceutical industries at home and abroad are speeding up resource integration. In particular, large pharmaceutical enterprises will build new business lines or core competitiveness by accelerating the acquisition of new companies; at the same time, an increasing number of unprofitable Biotech (start-up biotechnology enterprises) are also actively seeking survival through mergers and acquisitions after facing a capital chill.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.